Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pieris Pharmaceu's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pieris Pharmaceu's position in the market.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced its management team's participation in upcoming investor conferences. The Baird 2020 Virtual Global Healthcare Conference will take place on September 9, 2019, at 11:25 AM EDT, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2019, at 2:00 PM EDT. The company focuses on developing Anticalin® protein-based therapeutics targeting respiratory diseases and cancer. Additional details are available at www.pieris.com.